WeVote
Log In

Bill

Bill

SB 933

Health care; creating the Right to Try for Individualized Treatments Act; authorizing individualized investigational treatments for eligible patients. Effective date.

2026 Regular Session Introduced by Brenda Stanley and 1 co-sponsor

Oklahoma authorizes terminally/seriously ill patients to access unapproved experimental medical treatments outside FDA clinical trials.

Approved by Governor 05/06/2026
0
WeVote Research Nonpartisan
Bill Summary · SB 933

Legislative bill overview

SB 933 creates the "Right to Try for Individualized Treatments Act" in Oklahoma, which would authorize eligible patients to access investigational medical treatments that have not yet been approved by the FDA. This legislation aligns with federal right-to-try laws by establishing a state-level framework for terminally ill or seriously ill patients to attempt experimental therapies outside standard clinical trial processes.

Why is this important

Right-to-try laws address the tension between patient autonomy and medical safety oversight. They directly affect terminally ill Oklahomans who may exhaust conventional treatment options and wish to pursue experimental therapies as a last resort. The bill passed the Senate unanimously (41-0), suggesting broad bipartisan support for expanding patient access options.

Potential points of contention

  • Patient safety vs. access: Investigational treatments lack proven safety data; expanding access without rigorous oversight could expose vulnerable patients to ineffective or harmful therapies
  • Liability and accountability: Unclear standards regarding liability if experimental treatments cause harm or fail to benefit patients, and who bears financial responsibility
  • Regulatory coordination: Potential conflicts between state-level right-to-try provisions and federal FDA oversight; unclear how manufacturers participate and ensure adequate monitoring

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.